期刊文献+

卵巢癌细胞HLA Ⅰ类分子表达异常和TAP,LMP基因表达的关系 被引量:5

A Synchronistic Deficiency in Expression of HLA Class I Molecules and TAP/LMP Genes in Human Ovarian Cancer Cells
下载PDF
导出
摘要 目的:肿瘤细胞表达MHCⅠ类分子是激发肿瘤抗原特异性CTL进行肿瘤免疫治疗的关键,肿瘤细胞HLAⅠ类分子表达异常是肿瘤逃脱免疫监视的重要机制.我们探讨了卵巢癌细胞HLAⅠ类分子表达异常的分子基础.方法:本文以West-ern blot、免疫组化和流式细胞术检测卵巢癌细胞HLA Ⅰ类分子的表达,以RT-PCR检测TAP,IMP基因的表达,探讨肿瘤细胞HLA Ⅰ类分子表达异常的分子基础.结果:卵巢癌中HLA Ⅰ类分子表达异常相当普遍(5/8),并涉及抗原加工相关基因TAP,LMP基因表达异常.25℃培养肿瘤细胞可部分诱导Ⅰ类分子的表达;结论:卵巢癌HLA Ⅰ类分子表达异常与其Ⅰ类抗原加工途径异常有关. Objective: Full expression of class I HLA molecules on tumor cells is pivotal in priming the tumor antigen-specific CTLs for effective iramunotherapies. Tumor cells display abnonnal expression of HLA class I molecules in human ovarian carcinoma. Methods: In this study, the expression of class I molecules in human ovarian cancer cells was determined by using Western bloting, immunohistochemistry testing and flow cytometry. The mRNA of TAP (transporter associated with antigen processing) and LMP(low molecular weight polypeptide) were exannined at the same time by RT-PCR. Results: It has been shown that class I molecules were unable to be, or only weakly, expressed in five of eight ovarian cancer cell lines. On these cell lines abnormal in class I expression, no or only little mRNA were detected for TAP1, TAP2, LMP2 and(or) LMP7 genes. Class I expression, however, could be partially recovered by incubating the tumor cells at 25℃ when compared with those at 37℃ . Conclusion: The results suggested that the dysfunction of TAP and IMP genes, following by a defective expression of class I molecules, might be one of the mechanisms enable ovarian cancer cells to escape from immune surveillance.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 1999年第4期257-260,共4页 Chinese Journal of Cancer Biotherapy
基金 国家自然基金(398707150) 上海市科技发展基金资助(97XD14002)
关键词 卵巢肿瘤 HLAⅠ类分子 TAP LMP ovarian cancer class I HLA molecules TAP LMP
  • 相关文献

参考文献1

共引文献3

同被引文献38

  • 1吕雪莹,李大林,王君,谷金宇,李殿俊,杨秋霞.TAP基因转染提高其在肿瘤细胞系的表达[J].黑龙江医学,2004,28(7):510-512. 被引量:3
  • 2翟金霞,沈冲,叶冬青.抗原肽处理相关运载蛋白体基因多态性与1型糖尿病[J].中国慢性病预防与控制,2007,15(1):28-31. 被引量:3
  • 3葛海良,MitchellZHo,GoodmanJoelW.MHC-Ⅰ类分子在肿瘤浸润性淋巴细胞识别人黑色素瘤细胞中的作用[J].中国免疫学杂志,1997,13(3):153-156. 被引量:9
  • 4王秀梅,张卫群,陈波,何玲,阿力木太,哈那提,李锋,杨磊,秦江梅.MTHFR基因多态性与哈萨克族食管癌易感性[J].中国公共卫生,2007,23(8):937-938. 被引量:18
  • 5Lauvau G, Kakimi K, Niedermann G, Ostankovitch M, Yotnda P, Firat H, Chisari FV, van Endert PM. Human transporters associated with antigen processing (TAPs) select epitope precursor peptides for processing in the endoplasmic reticulum and presentation to T cells. J Exp Med 1999; 190: 1227-1240.
  • 6Powis SJ, Young LL, Joly E, Barker PJ, Richardson L, Brandt RP, Melief CJ, Howard JC, Butcher GW. The rat cim effect: TAP allele-dependent changes in a class Ⅰ MHC anchor motif and evidence against C-terminal trimming of peptides in the ER. Immunity 1996; 4:159-165.
  • 7Yan G, Shi L, Faustman D. Novel splicing of the human MHC-encoded peptide transporter confers unique properties. J Immunol 1999; 162:852-859.
  • 8Cao B, Tian X, Li Y, Jiang P, Ning T, Xing H, Zhao Y, Zhang C, Shi X, Chen D, Shen Y, Ke Y. LMP7/ TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogenesis 2005; 26: 1280-1284.
  • 9Reits EA, Griekspoor AC, Neefjes J. How does TAP pump peptides? insights from DNA repair and traffic ATPases. Immunol Today 2000; 21:598-600.
  • 10Steimle V, Otten LA, Zufferey M, et al. Complementation cloning of an MHC class Ⅱ transactivator mutated in hereditary MHC class Ⅱ deficiency (or bare lymphocyte syndrome )[J]. Cell, 1993,75:135.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部